Anti-CD22 CAR T Cell Therapy Active in R/R Acute Lymphoblastic Leukemia

Share this content:
Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy is safe, feasible, and clinically active in children and young adults.
Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy is safe, feasible, and clinically active in children and young adults.

Anti-CD22 chimeric antigen receptor (CAR) T-cell therapy is safe, feasible, and clinically active in children and young adults with relapsed/refractory acute lymphoblastic leukemia who have undergone prior CAR therapy.1

The study, which will be presented at the American Society of Hematology (ASH) 58th Annual Meeting & Exposition in San Diego, California, showed that 44% of 9 evaluable treated achieved complete marrow remission.

Of those, 7 had previously received treatment with anti-CD19 CAR T-cell therapy, 2 had received 2 prior transplantations, and all patients had undergone at least 1 prior allogeneic hematopoietic cell transplantation.

Six patients treated at dose level 1 required dose-escalation due to expansion at this level following dose-limiting toxicities in the second patient with grade 3 diarrhea. Three patients treated at dose level 2 without dose-limiting toxicities underwent dose escalation.

Researchers observed CAR expansion and cytokine release syndrome (CRS) in 6 patients with a maximum CRS grade 2, and detected CAR cells in the peripheral blood, cerebrospinal fluid, and bone marrow of all responders.

Investigators enrolled children and young adults with relapsed/refractory CD22+ hematologic malignancies. All patients underwent lymphodepleting chemotherapy with fludarabine on days –4, –3, and –2 and cyclophosphamide on day –2 followed by CAR T-cell infusion on day 0. Dose level 1 started at 3 x 105 transduced T-cells/kg and dose level 2 began at 1 x 106transduced T cells/kg.

RELATED: Darwinian Oncology Comes of Age: Evolutionary Biologists Offer Competing Theories of Cancer

These interim findings suggest that anti-CD22 CAR T-cell therapy may be feasible for both CAR-naive patients and for those who have previously been treated with anti-CD19 CAR T-cell therapy who are CD19 negative. Accrual for the study is ongoing.

Reference

  1. Shah NN, Stetler-Stevenson M, Yuan CM, et al. Minimal residual disease negative complete remissions following anti-CD22 chimeric antigen receptor (CAR) in children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Paper presented at: American Society of Hematology (ASH) 58th Annual Meeting & Exposition; December 3-6, 2016; San Diego, CA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs